1. Home
  2. ELVN vs TVTX Comparison

ELVN vs TVTX Comparison

Compare ELVN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

N/A

Current Price

$46.48

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

N/A

Current Price

$46.98

Market Cap

4.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELVN
TVTX
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.7B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
ELVN
TVTX
Price
$46.48
$46.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
15
Target Price
★ $74.33
$73.43
AVG Volume (30 Days)
1.2M
★ 1.9M
Earning Date
11-05-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
3.17
★ 92.89
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$55.96
Revenue Next Year
N/A
$48.63
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.79
$22.59
52 Week High
$62.32
$68.73

Technical Indicators

Market Signals
Indicator
ELVN
TVTX
Relative Strength Index (RSI) 49.64 35.71
Support Level $44.18 $41.75
Resistance Level $46.96 $48.60
Average True Range (ATR) 2.47 2.55
MACD -0.17 -0.02
Stochastic Oscillator 25.69 29.52

Price Performance

Historical Comparison
ELVN
TVTX

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: